We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · March 24, 2023

Role of Topical Nasal Decongestant Oxymetazoline as a Novel Therapeutic Option for Post-Acne Erythema

The Journal of Dermatology


Additional Info

The Journal of Dermatology
The role of the topical nasal decongestant oxymetazoline as a novel therapeutic option for post-acne erythema: A split-face, double-blind, randomized, placebo-controlled trial
J Dermatol 2023 Feb 20;[EPub Ahead of Print], C Washrawirul, T Puaratana-Arunkon, Y Chongpison, N Noppakun, P Asawanonda, C Kumtornrut

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading